Guangwei Xu Selected Research

Neoplasms (Cancer)

5/2022	The Role of Exosome MicroRNA-103 in the Proliferation and Invasion of Hepatoma Cells and Its Mechanism.
1/2022	Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.
1/2021	Genome-wide identification of m6A-associated functional SNPs as potential functional variants for thyroid cancer.
11/2020	Nucleotide de novo synthesis increases breast cancer stemness and metastasis via cGMP-PKG-MAPK signaling pathway.
12/2018	A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma.
10/2017	Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guangwei Xu Research Topics

Disease

8	Infections 01/2018 - 07/2002
7	Virus Diseases (Viral Diseases) 01/2018 - 11/2012
6	Neoplasms (Cancer) 05/2022 - 10/2017
6	Hepatitis B 01/2018 - 11/2012
2	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2020
2	Breast Neoplasms (Breast Cancer) 11/2020 - 11/2014
2	Ovarian Neoplasms (Ovarian Cancer) 10/2017 - 07/2017
2	Colorectal Neoplasms (Colorectal Cancer) 12/2003 - 06/2002
1	Liver Neoplasms (Liver Cancer) 05/2022
1	Thyroid Neoplasms (Thyroid Cancer) 01/2022
1	Papillary Thyroid Cancer 01/2022
1	Compression Fractures (Compression Fracture) 11/2020
1	Seizures (Absence Seizure) 01/2020
1	Lymphatic Metastasis 12/2003
1	Stomach Neoplasms (Stomach Cancer) 07/2002

Drug/Important Bio-Agent (IBA)

9	sodium-bile acid cotransporterIBA 01/2018 - 11/2012
3	Taurocholic Acid (Sodium Taurocholate)IBA 01/2018 - 07/2013
3	Amino Acids FDA Link 07/2013 - 11/2012
2	Antiviral Agents (Antivirals)IBA 10/2016 - 03/2014
1	SolutionsIBA 01/2022
1	VemurafenibIBA 01/2022
1	6-methyladenineIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	purineIBA 11/2020
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 11/2020
1	Guanosine Triphosphate (GTP)IBA 11/2020
1	Ligases (Synthetase)IBA 11/2020
1	NucleotidesIBA 11/2020
1	Uric Acid (Urate)IBA 11/2020
1	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 11/2020
1	CannabinoidsIBA 01/2020
1	Glycine Receptors (Glycine Receptor)IBA 01/2020
1	Cocaine (Cocaine HCl)IBA 01/2020
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 12/2018
1	Bexarotene (LGD1069)FDA Link 01/2018
1	Circular DNAIBA 01/2018
1	Retinoid X Receptor alphaIBA 01/2018
1	EnzymesIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Group II Phospholipases A2IBA 01/2018
1	Viral AntigensIBA 01/2018
1	Arachidonic Acid (Vitamin F)IBA 01/2018
1	EicosanoidsIBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	AlkaloidsIBA 10/2017
1	BerberineIBA 10/2017
1	Therapeutic UsesIBA 10/2017
1	AntioxidantsIBA 10/2017
1	niraparibIBA 10/2017
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2017
1	Type 4 Fibroblast Growth Factor ReceptorIBA 07/2017
1	Fibroblast Growth Factor 1 (FGF-1)IBA 07/2017
1	Small Interfering RNA (siRNA)IBA 10/2016
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 10/2016
1	huaierIBA 11/2014
1	SodiumIBA 03/2014
1	Bile Acids and Salts (Bile Acids)IBA 03/2014
1	MicroRNAs (MicroRNA)IBA 01/2014
1	Proteins (Proteins, Gene)FDA Link 07/2013
1	Peptides (Polypeptides)IBA 06/2013
1	Carcinoembryonic AntigenIBA 12/2003
1	AntigensIBA 12/2003
1	Monoclonal AntibodiesIBA 12/2003
1	Complementary DNA (cDNA)IBA 07/2002
1	ParaffinIBA 07/2002

Therapy/Procedure

3	Therapeutics 01/2022 - 03/2014
2	Drug Therapy (Chemotherapy) 05/2022 - 06/2002
1	Kyphoplasty 11/2020
1	Endoscopes 12/2003